Today’s Pick

A Unique Simulation Builds Empathy by Allowing People to Experience Dementia Symptoms

More than 7 million Americans are living with Alzheimer’s disease, and while most adults are familiar with the outward signs, the inner experience is in large part a mystery to those without the condition.

​Keep Reading​

Together With Cytonics

Invest in Stability

In a market that shifts by the week, investing in stability is a smart move — and biotech offers just that. The highs and lows of Wall Street have little effect on scientific advancement, so while the market swings, Cytonics is focused on building breakthrough osteoarthritis treatment with the potential to reverse joint degradation.
​
But Cytonics isn’t following the typical playbook. Instead of chasing venture dollars or Big Pharma buyouts, the company is backed by everyday investors like you. With 25 patents, a de-risked platform technology, and a successful Phase 1 trial, Cytonics is entering their next stage of growth — and you could be part of it. Over 6,000 shareholders have already invested through the company’s Reg A+ offering. Now it’s your turn to help reshape the future of medicine while owning a piece of it.

More Trending Stories

Pet Owners: Watch Out for Foxtail Seed Pods That Can Harm Your Dog or Cat This Summer

​Get Helpful Info​

The Power of Forgiveness: Why a Psychologist Advises Letting Go (and a Free Workbook to Get Started)

​Learn the Benefits​

Our Solar System May Indeed Have 9 Planets, Paper Finds

​A Potential Planet​

16 Heartwarming Words and Phrases That Don’t Have an English Equivalent

​Read the List​